Search bioRxiv⌕ Search

Biology subjects

Bhadra, A. K.

Publications and source records attributed to Bhadra, A. K..

4 recordsLinked to original sources

Progranulin deficiency promotes neuroinflammation through cathepsin B-mediated activation of the NLRP3 inflammasome

Haploinsufficiency of progranulin (resulting from mutations in the GRN gene) is a major genetic cause of frontotemporal dementia (FTD), which is characterized by profound changes in personality and behavior, progressive impairments in executive function, speech, language and/or movement, TDP-43 pathology, lysosomal dysfunction, and neuroinflammation. Studies in progranulin-deficient mouse models have demonstrated the critical role of neuroinflammation in disease pathogenesis, as deletion of NF-kB or complement factors prevents FTD-associated behavioral deficits. While progranulin is known to be anti-inflammatory, the precise molecular mechanism by which its deficiency triggers inflammatory cascades remain unclear. Here, we investigate the involvement of the NLRP3 inflammasome in progranulin-deficient models, including mice, human microglial cells, and patient fibroblasts. In Grn mice, we found increased levels of several inflammasome-related proteins, including procaspase-1 and cleaved IL-1{beta}. Similarly, GRN knockout (KO) microglia cells showed significant increases in levels of procaspase-1, NLRP3, and cleaved IL-1{beta}. Moreover, KO cells had increased NLRP3 oligomerization, suggesting that progranulin negatively regulates inflammasome assembly. We also investigated the potential link between lysosomal dysfunction and NLRP3 inflammasome activation in progranulin deficiency. We found that pharmacological inhibition of cathepsin B reduced NLRP3 inflammasome oligomerization as well as inflammatory cytokine expression in GRN KO cells. Additionally, siRNA knockdown of cathepsin B reduced levels of procaspase-1 and cleaved IL-1{beta} in GRN KO cells. Finally, we found that heterozygous GRN fibroblasts exhibited similar increases in procaspase-1 and cleaved IL-1{beta} levels, and these increases were corrected by treatment with an antisense oligonucleotide (ASO) that increase progranulin protein levels. Overall, our results demonstrate that progranulin deficiency promotes NLRP3 inflammasome assembly and activity through cathepsin B-mediated signaling, thereby establishing a mechanistic link between lysosomal dysfunction and increased inflammation. The ability of the GRN-targeting ASO to correct NLRP3-mediated inflammation highlights a promising therapeutic strategy for FTD-GRN and inflammation in other neurodegenerative disorders linked to progranulin deficiency.

neuroscience↗

Mutations in Hsp40 co-chaperone change the unique canonical inter-domain interactions stimulating LGMDD1 myopathy

Limb-girdle muscular dystrophy D1 (LGMDD1) is a rare, dominantly inherited neuromuscular disorder caused by mutations in the HSP40 co-chaperone DNAJB6, primarily in the GF or J-domains. Currently, no treatments are available, and a challenge in understanding the disease is identifying a specific client protein for DNAJB6 in skeletal muscle. Our previous research indicated that LGMDD1 GF domain mutants in Sis1 exhibit substrate-specific effects, influenced by HSP70 activity. Herein, we found that novel mutations in the J-domain similarly affected chaperone function. The J-domain mutants exhibited variable substrate processing, reduced binding affinity to client-substrate, and decreased stimulation of Ssa1 ATP hydrolysis, with these effects being substrate-conformer-specific. Our simulation studies noted differences in inter-domain interactions linked to the mutants, which influence the Hsp40-Hsp70 ATPase cycle. These mechanistic insights enhance our understanding of LGMDD1 myopathy and help to identify potential treatment strategies in the future. TeaserRecalibrating the inter-domain interface of the mutant protein could potentially serve as a key therapeutic strategy for LGMDD1 myopathy.

biochemistry↗

Disruption of the nascent polypeptide-associated complex leads to reduced polyglutamine aggregation and toxicity

The nascent polypeptide-associate complex (NAC) is a heterodimeric chaperone complex that binds near the ribosome exit tunnel and is the first point of chaperone contact for newly synthesized proteins. Deletion of the NAC induces embryonic lethality in many multi-cellular organisms. Previous work has shown that the deletion of the NAC rescues cells from prion-induced cytotoxicity. This counterintuitive result led us to hypothesize that NAC disruption would improve viability in cells expressing human misfolding proteins. Here, we show that NAC disruption improves viability in cells expressing expanded polyglutamine and also leads to delayed and reduced aggregation of expanded polyglutamine and changes in polyglutamine aggregate morphology. Moreover, we show that NAC disruption leads to changes in de novo yeast prion induction. These results indicate that the NAC plays a critical role in aggregate organization as a potential therapeutic target in neurodegenerative disorders.

cell biology↗

Myopathy mutations in DNAJB6 slow conformer specific substrate processing that is rescued by NEF modulation

Molecular chaperones, or heat shock proteins (HSPs), protect against the toxic misfolding and aggregation of proteins. As such, mutations or deficiencies within the chaperone network can lead to disease. In fact, dominant mutations in DNAJB6 (Hsp40/Sis1), an Hsp70 co-chaperone, leads to a protein aggregate myopathy termed Limb-Girdle Muscular Dystrophy Type D1 (LGMDD1). DNAJB6 client proteins and co-chaperone interactions in skeletal muscle are not known. Here, we used the yeast prion model client in conjunction with in vitro chaperone activity assays to gain mechanistic insights, and found that LGMDD1 mutants affect Hsp40 functions. Strikingly, the mutants changed the structure of client protein aggregates, as determined by altered distribution of prion strains. They also impair the Hsp70 ATPase cycle, dimerization, and substrate processing and consequently poison the function of wild-type protein. These results define the mechanisms by which LGMDD1 mutations alter chaperone activity and provide avenues for therapeutic intervention.

biochemistry↗